Skip to main content
Premium Trial:

Request an Annual Quote

Ventana and BD Biosciences to Co-Market DNA Microarrays and Analysis System

NEW YORK, July 11 – Ventana Medical Systems and BD Biosciences Clontech Laboratories have agreed to non-exclusively co-market their microarray products, the companies said Wednesday.

Together, the two companies will co-promote BD Biosciences’ DNA microarrays, and Ventana’s microarray analysis platform. Financial details of the deal were not disclosed.

BD Biosciences Clontech, based in Palo Alto, Calif, manufactures pre-spotted glass microarrays containing up to 3800 human, mouse, and rat DNA oligonucleotides. Ventana’s microarray analysis system automates slide staining for hybridizing DNA microarrays in gene expression and other experiments. 

Ventana, based in Tucson, Ariz., has partnered with Genicon Sciences to develop its microarray analysis system.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.